

## **Erratum**

**Corrigendum: Abd El Bary et al. Cost Effectiveness Analysis of Letrozole Compared with Tamoxifen as Initial Adjuvant Therapy for Postmenopausal Women with Endocrine Responsive Breast Cancer. *Kasr El-Aini J Clin Oncol Nucl Med.* 2009; 5(3-4): 11-17.**

**Naser Abd El Bary <sup>1</sup>, Mina Maher <sup>1</sup>, Mohamed Elsherbini <sup>1</sup>, Mohamed Abdeen <sup>2</sup>, Tarek Hashem <sup>1</sup>**

*<sup>1</sup> Clinical Oncology Department, Faculty of Medicine, Menoufia University, Shibin El-Kom, Egypt; <sup>2</sup> Clinical Oncology Department, Faculty of Medicine, Cairo University, Cairo, Egypt*

This corrigendum corrects the author list and affiliations of the article: Abd El Bary et al. Cost Effectiveness Analysis of Letrozole Compared with Tamoxifen as Initial Adjuvant Therapy for Postmenopausal Women with Endocrine Responsive Breast Cancer. *Kasr El-Aini J Clin Oncol Nucl Med.* 2009; 5(3-4): 11-17.

In response to a request supported by documents from the corresponding author, the name Dr. Mohamed Elsherbini was added to the list of authors and the affiliation of Dr. Mohamed Abdeen was mentioned.

The corrected version of this article replaces the primarily published one.